Kymera Therapeutics KYMR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$315M-1.2% | -$311.35M-5.5% | -$295.12M-7.1% | -$275.43M-14.3% | -$240.88M-7.6% | ||
| $8.29M-0.3% | $8.31M+0.5% | $8.27M+2.0% | $8.11M+1.8% | $7.96M+8.0% | ||
| $61.68M+3.0% | $59.9M+1.1% | $59.25M+1.5% | $58.35M+1.9% | $57.28M+4.1% | ||
| -$242.58M-4.2% | -$232.89M-2.2% | -$227.93M+9.2% | -$251.01M-7.2% | -$234.06M-20.3% | ||
| $1.42M-2.3% | $1.45M-36.4% | $2.28M+8.6% | $2.1M-65.6% | $6.09M-53.2% | ||
| -$712.52M-36.7% | -$521.06M— | —— | —— | —— | ||
| $1.01B+1.9% | $990.71M+244% | $288.26M-42.3% | $499.67M+95.7% | $255.35M-58.1% | ||
| $54.13M-77.1% | $236.76M+10,489% | $2.24M-99.2% | $268.18M+7,629% | -$3.56M-135% | ||
| -$244M-4.1% | -$234.34M-1.8% | -$230.21M+9.0% | -$252.92M-5.4% | -$239.96M-15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
